Abstract
The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Current Pharmaceutical Design
Title:Treating Cancer in Older and Oldest Old Patients
Volume: 21 Issue: 13
Author(s): G. Colloca, A. Corsonello, E. Marzetti, L. Balducci, F. Landi, M. Extermann, G. Scambia, M. Cesari, I. Carreca, S. Monfardini and R. Bernabei
Affiliation:
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Abstract: The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Export Options
About this article
Cite this article as:
Colloca G., Corsonello A., Marzetti E., Balducci L., Landi F., Extermann M., Scambia G., Cesari M., Carreca I., Monfardini S. and Bernabei R., Treating Cancer in Older and Oldest Old Patients, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612821666150130122536
DOI https://dx.doi.org/10.2174/1381612821666150130122536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Importance of Lost Minerals in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Statins and Oxidative Stress in the Cardiovascular System
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genetics and Vaccines in the Era of Personalized Medicine
Current Genomics Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus
Current Neurovascular Research Vascular Oxidative Stress: A Key Factor in the Development of Hypertension Associated with Ethanol Consumption
Current Hypertension Reviews Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews Reductive Stress: A New Concept in Alzheimer’s Disease
Current Alzheimer Research Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology The Impact of Opioids on Cardiac Electrophysiology
Current Cardiology Reviews Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences